IOVANCE BIOTHERAPEUTICS, INC. Net Change in Cash
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Net Change in Cash of -$52.28 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-06
- IOVANCE BIOTHERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $33.44M, a 40.28% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $56.00M.
- IOVANCE BIOTHERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$40.70M, a 113.06% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was $311.75M.
- IOVANCE BIOTHERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $47.01M.
- IOVANCE BIOTHERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$59.27M.
- IOVANCE BIOTHERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$56.84M, a 136.95% decline from fiscal 2022.
- IOVANCE BIOTHERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $153.85M, a 1242.60% increase from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$52.28M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $33.44M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $47.01M 10-K · filed 2026-02-24 | |||
| 2025-09-30 | $42.05M 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $16.36M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | $56.00M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | -$59.27M 10-K · filed 2026-02-24 | |||
| 2024-09-30 | -$10.78M 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | $53.79M 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | -$40.70M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$56.84M 10-K · filed 2026-02-24 | |||
| 2023-09-30 | $95.99M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $58.28M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $311.75M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $153.85M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | $40.48M 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | $30.19M 10-Q · filed 2023-08-08 | |||
| 2021-12-31 | $11.46M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |